Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Core Points - Scott+Scott Attorneys at Law LLP is investigating Alvotech for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1] - Alvotech develops and manufactures biosimilar medicines, focusing on therapeutic areas such as autoimmune, eye, bone disorders, and cancer [2] - On November 2, 2025, Alvotech received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA) for AVT05, a biosimilar candidate to Simponi®, indicating deficiencies that must be resolved before approval [3] - Following the FDA's announcement, Alvotech's stock price dropped approximately 34%, closing at $5.03 on November 3, 2025 [3]